Table 1.
Serum biologic drug concentration thresholds can vary based on inflammatory bowel disease (IBD) phenotype and the desired therapeutic outcome to target. Adapted from [27].
| Drug Type | IBD Type | Time Point (Week) |
Threshold (μg/mL) |
Therapeutic Outcome (Time Point) | TDM Assay | References |
|---|---|---|---|---|---|---|
| VDZ | UC | 2 | >28.9 | Clinical response (week 14) | ELISA | Dreesen et al., 2018 |
| VDZ | UC | 2 | >23.7 | Mucosal healing (week 14) | ELISA | Dreesen et al., 2018 |
| VDZ | CD | 6 | >13.8 | Endoscopic remission (6 months) | ELISA | Verstockt et al., 2020 |
| VDZ | CD | 6 | >19.9 | Biological remission (6 months) | ELISA | Verstockt et al., 2020 |
| VDZ | UC | 6 | >20.9 | Endoscopic improvement (week 14) | ELISA | Verstockt et al., 2020 |
| VDZ | UC | 6 | >23.9 | Clinical remission (week 14) | ELISA | Verstockt et al., 2020 |
| VDZ | CD | 14 | >30.1 | Endoscopic improvement (6 months) | ELISA | Verstockt et al., 2020 |
| VDZ | CD | 14 | >21.2 | Clinical remission (6 months) | ELISA | Verstockt et al., 2020 |
| VDZ | CD | 14 | >25.2 | Biological remission (6 months) | ELISA | Verstockt et al., 2020 |
| VDZ | UC | 14 | >10.1 | Endoscopic improvement (week 14) | ELISA | Verstockt et al., 2020 |
| VDZ | UC | 14 | >10.1 | Clinical remission (week 14) | ELISA | Verstockt et al., 2020 |
| VDZ | UC | 14 | >6.8 | Biological remission (week 14) | ELISA | Verstockt et al., 2020 |
| VDZ | UC | 14 | >12.6 | Clinical response (week 14) | ELISA | Dreesen et al., 2018 |
| VDZ | UC | 14 | >17 | Mucosal healing (week 14) | ELISA | Dreesen et al., 2018 |
| VDZ | CD | 22 | >13.6 | Mucosal healing (week 22) | ELISA | Dreesen et al., 2018 |
| VDZ | CD | 22 | >12 | Biological remission (week 22) | ELISA | Dreesen et al., 2018 |
| VDZ | CD/UC | Maintenance | >11.5 | CS-free clinical & biochemical remission | HMSA | Ungaro et al., 2019 |
| VDZ | CD/UC | Maintenance | >10.7 | CS-free endoscopic remission | HMSA | Ungaro et al., 2019 |
| VDZ | CD/UC | Maintenance | >14.8 | CS-free deep remission | HMSA | Ungaro et al., 2019 |
| VDZ | CD | Maintenance | >6.8 | CS-free clinical & biochemical remission | HMSA | Ungaro et al., 2019 |
| VDZ | UC | Maintenance | >10.1 | CS-free clinical & biochemical remission | HMSA | Ungaro et al., 2019 |
| VDZ | CD | Maintenance | >12.1 | Biological remission after 6 months | ELISA | Verstockt et al., 2020 |
| VDZ | CD | Maintenance | >10.1 | Endoscopic remission after 6 months | ELISA | Verstockt et al., 2020 |
| UST | CD | 4 | >15 | FC < 100 mg/g (week 16) | ELISA | Hanzel et al., 2020 |
| UST | CD | 4 | >23.7 | Endoscopic remission (week 24) | ELISA | Hanzel et al., 2020 |
| UST | CD | 8 | >4.2 | 50% decrease in FC (week 8) | ELISA | Verstockt et al., 2019 |
| UST | CD | 8 | >7.2 | Biological remission (week 8) | ELISA | Verstockt et al., 2019 |
| UST | CD | 8 | >4.4 | FC < 100 mg/g (week 16) | ELISA | Hanzel et al., 2020 |
| UST | CD | 8 | >6.9 | FC < 100 mg/g (week 24) | ELISA | Hanzel et al., 2020 |
| UST | CD | 8 | 11.1 | Endoscopic remission (week 24) | ELISA | Hanzel et al., 2020 |
| UST | UC | 8 | >3.7 | Clinical response (week 8) | ELISA | Adedokun et al., 2019 |
| UST | UC | 8 | >3.5 | Endoscopic improvement (week 8) | ELISA | Adedokun et al., 2019 |
| UST | UC | 8 | >3.7 | Histologic improvement (week 8) | ELISA | Adedokun et al., 2019 |
| UST | UC | Maintenance | ≥1.3 | Clinical remission (week 44) | ELISA | Adedokun et al., 2019 |
| UST | UC | Maintenance | ≥1.1 | Endoscopic improvement (week 44) | ELISA | Adedokun et al., 2019 |
| UST | UC | Maintenance | ≥1.3 | Histologic improvement (week 44) | ELISA | Adedokun et al., 2019 |